Methods and systems for determining a likelihood of adverse prostate cancer pathology
AssigneeThe Regents of the University of California
InventorsRobert Hector Blelloch, Siao-Yi Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods that find use in determining a likelihood of adverse prostate cancer pathology in a subject. The methods generally involve detection of one or more diagnostic microRNAs (miRNAs), such as mir-19a, mir-19b, mir-519c-5p, and/or mir-345 in a biological sample from the subject, such as blood or blood product. The detection of one or more such diagnostic miRNAs can be used to determine a likelihood of adverse prostate cancer pathology in a subject. The methods of the present disclosure also find use in facilitating treatment decisions for a subject. Also provided are devices, systems, and kits that may be used in practicing methods of the present disclosure.
Claims11
A method comprising:
- determining an amount of each miRNA in a set of miRNAs consisting of:
- mir-19a, mir-519c-5p, and mir-345;
- or
- mir-19b, mir-519c-5p, and mir-345,
- in a sample of blood or blood product from a male human subject suspected of having prostate cancer, by
- a) reverse transcribing RNA from the sample using a primer that hybridizes with mir-19a, mir-19b, mir-519c-5p or mir-345, to generate a reverse transcription product encoding mir-19a, mir-19b, mir-519c-5p or mir-345 and
- b) detecting an amount of the reverse transcription product encoding mir-19a, mir-19b, mir-519c-5p or mir-345.
Dependencies are inferred from the claim text.